Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience

Asil S., Kaya B., CANPOLAT U., YORGUN H., Sahiner L., ÇÖTELİ C., ...Daha Fazla

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, cilt.92, sa.3, ss.557-565, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 92 Sayı: 3
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1002/ccd.27442
  • Dergi Adı: CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.557-565
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Aims: Percutaneous septal reduction therapy by either alcohol or nonalcohol agents is an alternative approach to surgery in drug-refractory symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM). Nonalcohol agents have some advantages and disadvantages over alcohol during the procedure. Nowadays, a novel non-alcohol agent, named as Ethylene-vinyl alcohol (EVOH) copolymer (Onyx (R) and Squid (R)), is used during septal ablation. Thus, in this study, we aimed to evaluate both acute and long-term efficacy and safety profile of EVOH during septal ablation in HOCM.